Skip to content

June 2026

Psychedelic-assisted therapy

What June 2026's 20 new studies found, synthesized from the papers below. All Psychedelic-assisted therapy research →

The synthesis

Synthesized from 20 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Psychedelic-assisted therapy, psychedelic therapy, assisted psychotherapy, drug-assisted therapy, then ranked by relevance.

Research in June 2026 found that MDMA-assisted psychotherapy shows a moderate-to-large reduction in PTSD symptoms, while ketamine's effect on PTSD was small and non-significant. For depression, real-world ketamine-assisted psychotherapy practices vary widely, and a pilot trial suggests ketamine-assisted psychotherapy may be acceptable for methamphetamine use disorder. However, the evidence base remains constrained by poor study quality, heterogeneity in protocols, and unresolved issues like blinding and expectancy effects.

Confidence in the evidence

Low-Moderate
  • One meta-analysis of 11 RCTs (358 participants) found MDMA effective for PTSD but ketamine non-significant, though many included studies were of poor quality.
  • A systematic review and IPDMA of 12 studies (533 participants) on ketamine for PTSD found greater improvement with more sessions but high heterogeneity and poor quality in most studies.
  • A cross-sectional survey of 50 providers showed wide variability in KAP practices, indicating lack of standardization.
  • Qualitative and pilot studies (e.g., for methamphetamine use disorder) are small and open-label, limiting generalizability.
  • Several reviews highlight unresolved methodological challenges such as blinding difficulties, expectancy effects, and lack of active comparators.
How we rate confidence

Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.

Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.

Evidence by study

Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.

This scoping review categorized psychosocial protocols across 62 studies, finding limited reporting and heterogeneity as major challenges.

scoping review · Sample size: 62

Participants described reduced emotional and cognitive reactivity after ketamine sessions and valued relational safety and clinical containment.

qualitative · Sample size: 14

Greater PTSD symptom improvement was associated with more psychotherapy sessions, more ketamine sessions, higher baseline severity, and shorter treatment duration, but between-study heterogeneity was non-trivial and most studies were of poor quality.

systematic review and individual participant data meta-analysis · Sample size: 533

Music use in PAP varied considerably across 36 articles, with no standardized protocol, predominantly addressing depressive disorders and PTSD using psilocybin and MDMA.

systematic review · Sample size: 36

The strongest evidence for addiction treatment comes from a limited number of randomized studies, while most literature remains observational or open-label, suggesting cautious clinical potential rather than established effectiveness.

narrative review

Ethical challenges in KAP included inequitable access, difficulties with informed consent due to ketamine's unpredictability, and risks of fragmented care when ketamine is treated as a stand-alone cure.

qualitative · Sample size: 16

64.3% of participants were willing to participate in a psychedelic therapy trial, with willingness significantly associated with higher expectations of research success.

mixed-method · Sample size: 112

Real-world KAP practices varied widely, with most providers using eclectic approaches and no significant association between psychotherapy modalities and treatment goals.

cross-sectional survey · Sample size: 50

MDMA-assisted psychotherapy showed a significant moderate-to-large reduction in PTSD symptoms, while the pooled effect for ketamine was small and non-significant, and a single cannabidiol trial showed no clear benefit.

systematic review and meta-analysis · Sample size: 358

A direct observation coding system for awe narration was developed and refined, with coders identifying 246 moments of awe narration across 16,760 minutes of video.

observational · Sample size: 8

Recent larger-scale phase 3 trials of psilocybin for treatment-resistant depression have shown more modest effects, and the long-term trajectory of psychedelic therapies in public health systems remains uncertain.

theoretical/policy review

Conflicting musical features were found across modern PAT, traditional entheogenic rituals, and musically-induced peak experiences, with recommendations to tailor music to the drug, individual, and desired experience.

interdisciplinary literature review

The relational spirituality model was proposed as a framework for developing spiritual and religious competencies in psychedelic-assisted psychotherapy training.

theoretical

Only 19 papers met inclusion criteria for quantitative research on music and psychedelics, with psilocybin and LSD most studied and no studies on MDMA and music.

scoping review · Sample size: 330

Survey responses indicated strong PSW support for PAT, with most willing to recommend it to clients, though qualitative findings highlighted concerns about safety, psychoeducation, stigma, and accessibility.

cross-sectional survey with qualitative interviews

Psychology students reported significantly higher knowledge, more positive attitudes, and greater openness to psychedelics than medical students.

cross-sectional survey · Sample size: 360

This commentary argued that the evidence base for MDMA-assisted psychotherapy for PTSD remains constrained by difficulties in blinding, expectancy effects, lack of active comparators, and limited mechanistic clarity.

commentary

Focus groups underscored the value of meaning-centered psychotherapy as a framework for psilocybin-assisted therapy, leading to the development of a 5-session MCP-PSIL model.

qualitative · Sample size: 13

This article applied Bion's theory of containment to neurobiological models of trauma and the effects of MDMA and classic psychedelics.

theoretical

This conceptual article proposed a systemic approach to psychedelic-assisted psychotherapy that includes relational figures and measures relational quality, attachment, and communication patterns.

theoretical

Points of agreement

  • MDMA-assisted psychotherapy shows a promising efficacy signal for PTSD symptom reduction across multiple reviews.
  • There is broad recognition that methodological challenges (blinding, expectancy, heterogeneity) limit the current evidence base.
  • Music is considered an important component of psychedelic-assisted therapy, but standardized protocols are lacking.
  • Qualitative studies highlight the importance of therapeutic context, relational safety, and integration sessions.

Conflicts

  • MDMA showed a significant moderate-to-large effect on PTSD in one meta-analysis, while ketamine's effect was small and non-significant in the same analysis, but another IPDMA found positive predictors for ketamine-assisted psychotherapy.
  • Phase 3 trials of psilocybin for treatment-resistant depression have shown more modest effects compared to earlier phase 2 trials.
  • Real-world KAP practices vary widely with no clear logic linking psychotherapy modalities to treatment goals.

Gaps

  • Long-term durability of treatment gains is not well established.
  • Most studies are small, open-label, or of poor quality; large, well-controlled RCTs are needed.
  • Standardized protocols for music, psychotherapy modalities, and dosing are lacking.
  • Research on psychedelic-assisted therapy in diverse populations and conservative cultural settings is scarce.
  • Mechanistic clarity and active comparator conditions are missing from most trials.
Browse these studies in the library